Gunjan Bagla

Based in Los Angeles, Gunjan Bagla is managing director of Amritt Inc., a California-based consulting firm focused on helping American companies to succeed in India. His clients include Covidien, Roche Diagnostics, BD, Nordic Naturals, Johnson & Johnson, Gojo, and many more. Gunjan spoke three times at the MD&M West Conference in Anaheim, and was on the keynote panels at MEDevice San Diego and IMDI in Ahmedabad, India. For his India expertise, he has appeared in The New York Times, the Los Angeles Times, and the Washington Post, and on Bloomberg TV, BBC Television, and Fox Business News. He also writes about India for the Harvard Business Review and the Huffington Post. Gunjan has an MBA from Southern Illinois University and a mechanical engineering degree from the Indian Institute of Technology (IIT) Kanpur in India.


  • How Will India's New Healthcare Budget Help Medical Device Manufacturers?

    India's Finance Minister Nirmala Sitharaman announced an astounding 137% increase in spending for health and well-being for the fiscal year. This article focuses on the $8.2 billion portion of the budget allocated for the prime minister’s Healthy Indian Plan, which affects medical device developers.

  • Pandemic Prompts Supply Chain Exodus From China — What's Best For Your Business?

    Decisions made in panic rarely work out for the best. In lieu of abandoning operations in China completely, consider these alternatives to secure your company’s supply chain.

  • India To Regulate All Medical Devices

    Expansion of notified device categories is poised to benefit savvy domestic and Western medical device companies by cutting out cut-rate operations.


  • India To Enhance Oversight Of Medical Devices

    India's Central Drugs Standard Control Organization (CDSCO), the country’s national regulatory authority for both drugs and medical devices, is forming a new division that works exclusively with medical devices. Here’s what we know so far.

  • Four Ways MedTech Can Thrive In Emerging Markets

    Just two percent of the revenues generated by the top 200 medical device companies arise from emerging markets. To achieve greater success, medtech must look beyond the legacy approaches that led to success serving the billion richest patients in the world.

  • Startups Illustrating The Future Of Global Medtech

    Globally aware CEOs are looking beyond rich country patients for long-term growth. This article highlights a pair of startups attempting to bring innovation large, under-served populations, and analyzes the effectiveness of their approach.

  • Massive Insurance Plan In India Will Open New Markets For Medical Devices

    India’s federal government recently announced a plan to offer free medical insurance to over 500 million of its poorest citizens. Astute medical device companies can leverage this opportunity to build new businesses while transforming the lives of millions of families who presently lack access to the most basic procedures.

  • Medtech Innovations For Diagnostics In India

    Before you can treat a disease, you need to know it exists in a patient. Across the developing world, diagnosis is a major challenge, with hundreds of millions of patients being missed by the healthcare systems due to poor access, high costs, or lack of skilled staff. This article looks at four companies from India that have approached this problem from radically different angles — with impressive results.

  • India Looking To Local Solutions For Domestic Medtech Needs

    For most of the last century, innovation in the medical device ecosystem has emerged from rich countries: the United States, Japan, Europe, and Australia. But today, a thriving ecosystem has developed across India, driven in part by unique needs in India and in part by the cross-fertilization of ideas, education, and capital from American sources. In this article, we look at three startups that are addressing India’s unique problems today, but may eventually bring their solutions to a global audience.